Drug Profile
CT 365
Alternative Names: CT365Latest Information Update: 17 Sep 2023
Price :
$50
*
At a glance
- Originator HEC Pharm
- Class Antifibrotics; Antineoplastics; Small molecules
- Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; MTOR protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Idiopathic pulmonary fibrosis; Solid tumours
Most Recent Events
- 17 Sep 2023 CT 365 is still in preclinical development for Idiopathic-pulmonary-fibrosis and Solid tumours in China (unspecified route)
- 28 Sep 2020 No recent reports of development identified for preclinical development in Idiopathic-pulmonary-fibrosis in China
- 28 Dec 2019 No recent reports of development identified for preclinical development in Solid-tumours in China